S&P 500   2,989.65 (-0.20%)
DOW   27,010.75 (-0.05%)
QQQ   192.86 (-0.34%)
AAPL   234.03 (-0.55%)
FB   189.14 (+0.13%)
MSFT   140.19 (-0.98%)
GOOGL   1,243.12 (+0.07%)
AMZN   1,779.22 (+0.67%)
CGC   19.67 (-2.14%)
NVDA   194.01 (-1.20%)
MU   45.17 (-2.76%)
GE   8.94 (+0.45%)
TSLA   258.32 (+0.17%)
AMD   30.86 (+0.46%)
T   37.84 (-0.16%)
F   9.08 (+0.11%)
ACB   3.64 (-3.19%)
BAC   30.36 (+2.09%)
GILD   65.47 (+0.26%)
DIS   130.86 (+0.85%)
S&P 500   2,989.65 (-0.20%)
DOW   27,010.75 (-0.05%)
QQQ   192.86 (-0.34%)
AAPL   234.03 (-0.55%)
FB   189.14 (+0.13%)
MSFT   140.19 (-0.98%)
GOOGL   1,243.12 (+0.07%)
AMZN   1,779.22 (+0.67%)
CGC   19.67 (-2.14%)
NVDA   194.01 (-1.20%)
MU   45.17 (-2.76%)
GE   8.94 (+0.45%)
TSLA   258.32 (+0.17%)
AMD   30.86 (+0.46%)
T   37.84 (-0.16%)
F   9.08 (+0.11%)
ACB   3.64 (-3.19%)
BAC   30.36 (+2.09%)
GILD   65.47 (+0.26%)
DIS   130.86 (+0.85%)
Log in

BioMark Diagnostics Stock Price, News & Analysis (CNSX:BUX)

Today's Range N/A
50-Day Range
$0.11
MA: $0.14
$0.17
52-Week Range N/A
Volume40,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-370-0779

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BUX News and Ratings via Email

Sign-up to receive the latest news and ratings for BUX and its competitors with MarketBeat's FREE daily newsletter.


BioMark Diagnostics (CNSX:BUX) Frequently Asked Questions

What is BioMark Diagnostics' stock symbol?

BioMark Diagnostics trades on the CNSX under the ticker symbol "BUX."

Has BioMark Diagnostics been receiving favorable news coverage?

News articles about BUX stock have trended positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMark Diagnostics earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for BioMark Diagnostics.

Who are some of BioMark Diagnostics' key competitors?

Who are BioMark Diagnostics' key executives?

BioMark Diagnostics' management team includes the folowing people:
  • Mr. Rashid Ahmed Bux, Founder, CEO, Pres & Director
  • Mr. Brian Cheng, CTO & Director
  • Gina Huang, CFO & Project Director
  • Dr. Thomas Malcolm Ph.D., Chief Scientific Officer
  • Neal Kaplan, Chief Financial Officer of US

How do I buy shares of BioMark Diagnostics?

Shares of BUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioMark Diagnostics' official website?

The official website for BioMark Diagnostics is http://www.biomarkdiagnostics.com/.

How can I contact BioMark Diagnostics?

The company can be reached via phone at 604-370-0779.


MarketBeat Community Rating for BioMark Diagnostics (CNSX BUX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  21
MarketBeat's community ratings are surveys of what our community members think about BioMark Diagnostics and other stocks. Vote "Outperform" if you believe BUX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BUX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel